CDY
Director Trades
| Date | Director | Value |
|---|
Company News
Cellmid set to commercialise 15 minute diagnostic test for COVID-19
Life sciences company Cellmid (ASX: CDY) is set to come out of its self-imposed trading halt on Monday with news that it will commercialise a rapid test capable of detecting coronavirus (COVID-19) within 15 minutes. First developed in China by biotech company Guangzhou Wondfo Biotech, the diagnostic test is set to be used as a […]
Cellmid prepares to receive Chinese patent covering évolis range
Life sciences company Cellmid (ASX: CDY) has told the market it is tentatively expecting to receive a patent from the Chinese Patent Office for its évolis brand in the very near future. Earlier today, Cellmid said that Chinese authorities had issued a notice of intention to grant in relation to its patent titled “Method of treatment of […]
Cellmid launches evolis hair products into Europe and China via new distribution agreements
Cellmid (ASX: CDY) has launched into Europe after securing a distribution agreement with Douglas GmbH for its evolis professional anti-aging hair care and hair loss products, while at the same time collaring a distribution agreement in China with Aeon International for the same products. Douglas is a leading German beauty retailer and will initially focus […]
Cellmid predicts record second quarter revenue after successful Japanese sales campaign
Australian life sciences company Cellmid (ASX: CDY) has reaped a revenue of approximately $1.1 million from a scheduled sales event for its Jo-Ju hair growth products in Japan. The figure will contribute to the company’s expected record sales revenue for second quarter 2019 of more than $2m. Cellmid’s promotion of the repackaged Jo-Ju line on […]
Cellmid’s anti-midkine study holds promise for chronic kidney disease patients
Australian life sciences company Cellmid (ASX: CDY) has announced positive efficacy results of a study using its anti-midkine antibody CAB102 in the treatment of rare kidney disease focal segmental glomerulosclerosis. The study, performed at the Westmead Institute for Medical Research, confirmed previous findings that blocking midkine alleviates damage to the kidney and prevents ensuing defects […]
Cellmid executes pincer movement to distribute cornerstone évolis product into both China and the US
With the US-China trade war brewing in the background, life sciences company Cellmid (ASX: CDY) has secured a deal to sell its évolis product in China – barely a week after agreeing to supply the same product into the US via retailing giant Bloomingdale’s. Via its subsidiary Advangen, Cellmid has entered into an exclusive agreement […]
Positive study results for Cellmid’s évolis hair growth products
Cellmid Limited (ASX: CDY) has reported positive results following the completion of its first consumer experience study using the evolis® Professional product range. All but one of the study participants (98%) recorded new hair growth and 97% reported decreased hair fall using the full range of the company’s evolis® Professional products over 120 days. In […]
Company Videos
No videos found.